Literature DB >> 23865106

Special report: multiple molecular testing of cancers to identify targeted therapies.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23865106

Source DB:  PubMed          Journal:  Technol Eval Cent Assess Program Exec Summ


× No keyword cloud information.
  6 in total

1.  Clinical integration of next generation sequencing: coverage and reimbursement challenges.

Authors:  Patricia A Deverka; Jennifer C Dreyfus
Journal:  J Law Med Ethics       Date:  2014       Impact factor: 1.718

2.  Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.

Authors:  Julia R Trosman; Christine B Weldon; R Kate Kelley; Kathryn A Phillips
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

3.  Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.

Authors:  Michael Marrone; Kelly K Filipski; Elizabeth M Gillanders; Sheri D Schully; Andrew N Freedman
Journal:  PLoS Curr       Date:  2014-05-27

Review 4.  Overview of a chemoresponse assay in ovarian cancer.

Authors:  E C Grendys; J V Fiorica; J W Orr; R Holloway; D Wang; C Tian; J K Chan; T J Herzog
Journal:  Clin Transl Oncol       Date:  2014-07-02       Impact factor: 3.405

Review 5.  Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.

Authors:  Kathryn A Phillips; Patricia A Deverka; Harold C Sox; Muin J Khoury; Lewis G Sandy; Geoffrey S Ginsburg; Sean R Tunis; Lori A Orlando; Michael P Douglas
Journal:  Genet Med       Date:  2017-04-13       Impact factor: 8.822

6.  Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.

Authors:  Christine Y Lu; Stephanie Loomer; Rachel Ceccarelli; Kathleen M Mazor; James Sabin; Ellen Wright Clayton; Geoffrey S Ginsburg; Ann Chen Wu
Journal:  J Pers Med       Date:  2018-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.